Cardiovascular effects of antimuscarinic agents in overactive bladder

Bibliography

• Haylen BT, de Ridder D, Freeman RM, et al. International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4-20
   PubMed Web of Science ®Google Scholar
• Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010;21:5-26
   PubMed Web of Science ®Google Scholar
• Stewart WF, Corey R, Herzog AR, et al. Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynecol J 2001;12:S66
   Google Scholar
• Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008;101:1388-95
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-14
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Bell JA, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn 2012; Epub ahead of print
   Google Scholar
• Cardozo L. Systematic review of overactive bladder therapy in females. Can Urol Assoc J 2011;5:S139-42
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body sistems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148:565-78
   PubMed Web of Science ®Google Scholar
• Matsui M, Motomura D, Karasawa H, et al. Multiple funcional defects in peripheral autonomic organs in mice lacking muscarinic acetylcoline receptor gene for the M3 subtype. Proc Natl Acad Sci USA 2000;97:9579-84
   PubMed Web of Science ®Google Scholar
• Hedge SS, Eglen RM. Muscarinic receptor subtypes modulating sooth miscle contractility in the urinary bladder. Life Sci 1999;64:419-28
   PubMed Web of Science ®Google Scholar
• Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol 2002;22:133-45
   PubMedGoogle Scholar
• Leone Roberti Maggiore U, Salvatore S, Alessandri A, et al. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Expert Opin Drug Metab Toxicol 2012;8:1387-408
   PubMed Web of Science ®Google Scholar
• Orefelein MG. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf 2011;34:733-54
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007;100:987-1006
   PubMed Web of Science ®Google Scholar
• Harrington AM, Peck CJ, Liu L, et al. Localization of muscarinic receptors M1R, M2R and M3R in the human colon. Neurogastroenterol Motil 2010;22:999-1008
   PubMed Web of Science ®Google Scholar
• Ishizaka N, Noda M, Yokoyama S, et al. Muscarinic acetylcholine receptor subtypes in the human iris. Brain Res 1998;787:344-7
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 2008;71:449-54
   PubMed Web of Science ®Google Scholar
• Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nerous system effects. CNS Neurosci Ther 2012;18:167-74
   PubMed Web of Science ®Google Scholar
• Asche CV, Kim J, Kulkarni AS, et al. Presence of central nervous system, cardiovascular and overall co-morbility burden in patients with overactive bladder disorder in a real-word setting. BJU Int 2011;109:572-80
   PubMed Web of Science ®Google Scholar
• Andersson KE, Sarawate C, Kahler KH, et al. Cardiovascular morbility, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int 2010;106:268-74
   PubMed Web of Science ®Google Scholar
• Harvey RD. Muscarinic receptor agonists and antagonists: effect on cardiovascular function. In: Fryer AD, Christopoulos A, Nathanson NM, editors. Muscarinic receptors, handbook of experimental pharmacology. Springer-Verlang; Berlin Heidelberg: 2012. p. 299-316
   Google Scholar
• Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding disfunction. Br J Clin Pharmacol 2011;72:186-96
   PubMed Web of Science ®Google Scholar
• Stengel PW, Gomeza J, Wess J, et al. M(2) and M(4) receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J Pharmacol Exp Ther 2000;292:877-85
   PubMed Web of Science ®Google Scholar
• Dhein S, Van Koppen CJ, Brodde OE. Muscarinic receptors in the mammalian heart. Pharmacol Res 2001;44:161-82
   PubMed Web of Science ®Google Scholar
• Abramochkin DV, Suris MA, Borodinova AA, et al. M3 cholinoreceptors: new mediator of acetylcholine action on myocardium. Neurochem J 2008;2:90-4
   Google Scholar
• Wang H, Shi H, Lu Y, et al. Pilocarpine modulates the cellular electrical properties of mammalian hearts by activating a cardiac M3 receptor and a K+ current. Br J Pharmacol 1999;126:1725-34
   PubMed Web of Science ®Google Scholar
• Abramochkin DV, Tapilina SV, Sukhova GS, et al. Functional M3 cholinoreceptors are present in pacemaker and working myocardium of murine heart. Eur J Physiol 2012;463:523-9
   PubMed Web of Science ®Google Scholar
• Wang Z, Shi H, Wang H. Functional M3 muscarinic acetylcholine receptors in mammalian hearts. Br J Pharmacol 2004;142:395-408
   PubMed Web of Science ®Google Scholar
• Cook S, Togni M, Schaub MC, et al. High heart rate: a cardiovascular risk factor? Eur Heart J 2006;27:2387-93
   PubMed Web of Science ®Google Scholar
• Majercak I. The use of heart rate variability in cardiology. Bratisl Lek Listy 2002;103:368-77
   PubMedGoogle Scholar
• Gutman GA, Chandy KG, Grissner S, et al. International union of pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 2005;57:473-508
   PubMed Web of Science ®Google Scholar
• Witchel HJ. Drug-induced hERG block and long QT syndrome. Cardiovasc Ther 2011;29:251-9
   PubMed Web of Science ®Google Scholar
• Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca2+ release causes myocyte depolarization-underlying mechanism and threshold for triggered action potentials. Circ Res 2000;87:774-80
   PubMed Web of Science ®Google Scholar
• Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270(21):2590-7
   PubMed Web of Science ®Google Scholar
• Liu XK, Wang W, Ebert SN, et al. Female gender is a risk factor for torsades de pointes in an in vitro animal model. J Cardiovasc Pharmacol 1999;34(2):287-94
   PubMed Web of Science ®Google Scholar
• Shuba YM, Degtiar VE, Osipenko VN, et al. Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. Biochem Pharmacol 2001;62(1):41-9
   PubMed Web of Science ®Google Scholar
• Liu XK, Katchman A, Whitfield BH, et al. In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits. Cardiovasc Res 2003;57(1):28-36
   PubMed Web of Science ®Google Scholar
• Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50(2):222-39
   PubMed Web of Science ®Google Scholar
• Mao J, Scherlag BJ, Liu Y, et al. The atrial neural network as a substrate for atrial fibrillation. J Interv Card Electrophysiol 2012;35:3-9
   PubMed Web of Science ®Google Scholar
• Yamada S, Maruyama S, Takagi Y, et al. In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice. Life Sci 2006;80:127-32
   PubMed Web of Science ®Google Scholar
• Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005;95:993-1001
   PubMed Web of Science ®Google Scholar
• Green L, Kerney D. Patient experience with darifenacin - results of a short-term community- based survey in managing overactive bladder. Curr Med Res Opin 2011;27:431-7
   PubMed Web of Science ®Google Scholar
• Kay GG, Wesnes KA. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 2005;96:1055-62
   PubMed Web of Science ®Google Scholar
• Nichols D, Colli E, Goka J, et al. Darifenacin demonstrated no adverse effect on cognitive and cardiac functions: results from a double-blind, rabdomized, placebo-controlled study [abstract]. Neurourol Urodyn 2006;20:354
   Google Scholar
• Olshansky B, Ebinger U, Brum J, et al. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants ≥ 50 years. J Cardiovasc Pharmacol Ther 2008;13:241-51
   PubMed Web of Science ®Google Scholar
• Serra DB, Affrime MB, Bedigian MP, et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 2005;45:1038-47
   PubMed Web of Science ®Google Scholar
• Kraus SR, Ruiz-Cerdá JL, Martire D, et al. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2010;76:1350-7
   PubMed Web of Science ®Google Scholar
• Malhotra BK, Wood N, Sachse R. Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther 2009;47:570-8
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Tubaro A, Wang JT, et al. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int 2008;102:56-61
   PubMed Web of Science ®Google Scholar
• Van Kerrebroeck PEV, Heesakkers J, Berriman S, et al. Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. Int J Clin Pract 2010;64:584-93
   PubMed Web of Science ®Google Scholar
• Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007;178:2488-94
   PubMed Web of Science ®Google Scholar
• Chapple C, Van Kerrebroeck PEV, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007;52:1204-12
   PubMed Web of Science ®Google Scholar
• Toviaz® (fesoterodine fumarate). US prescribing information. Pfizer, Inc; New York: 2012
   Google Scholar
• Malhotra B, Wood N, Sachse R, et al. Thorough QT study of the effect of fesoterodine on cardiac repolarization. Int J Clin Pharmacol Ther 2010;48:309-18
   PubMed Web of Science ®Google Scholar
• Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8s-21s
   PubMed Web of Science ®Google Scholar
• Malhotra B, Alvey C, Gong J, et al. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Br J Clin Pharmacol 2011;72:257-62
   PubMed Web of Science ®Google Scholar
• Kobayashi F, Yageta Y, Segawa M, et al. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung 2007;57:92-100
   PubMed Web of Science ®Google Scholar
• Nishijima S, Sugaya K, Kadekawa K, et al. Comparison of the effect of antimuscarinic agents on bladder activity, urinary ATP level and autonomic nervous system in rats. Biomed Res 2009;30:107-12
   PubMed Web of Science ®Google Scholar
• Homma Y, Yamaguchi O. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2009;16:499-506
   PubMed Web of Science ®Google Scholar
• Hasegawa C, Ohno T, Nakade S, et al. population pharmacokinetics and exposure–response relationship of a muscarinic receptor antagonist, imidafenacin. Drug Metab Pharmacokinet 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Nakade S, Ohno T, Nakayama K, et al. No Effect of Imidafenacin, a Novel Antimuscarinic Drug, on Digoxin Pharmacokinetics in Healthy Subjects. Drug Metab Pharmacokinet 2008;23:95-100
   PubMed Web of Science ®Google Scholar
• Jirschele K, Sand PK. Oxybutynin: past, present, and future. Int Urogynecol J 2012; Epub ahead of print
   Web of Science ®Google Scholar
• Baigrie RJ, Kelleher JP, Fawcett DP, et al. Oxybutynin: is it safe? Br J Urol 1988;62:319-22
   PubMedGoogle Scholar
• Ditropan® (Oxybitynin Chloride) tablets and syrup. US prescribing information. Ortho-McNeil Pharmaceutical, Inc; Raritan (NJ): 2008
   Google Scholar
• Ditropan XL® (Oxybutynin Chloride) extended release tablets. US prescribing informations. Ortho-McNeil-Janssen Pharmaceuticals, Inc; Raritan (NJ): 2009
   Google Scholar
• Abrams P, Cardozo L, Chapple C, et al. 1032 study group. Comparison of the efficacy, safety and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 2006;13:692-8
   PubMed Web of Science ®Google Scholar
• Chapple CR, Abrams P. Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. Eur Urol 2005;48:102-9
   PubMed Web of Science ®Google Scholar
• Hussain RM, Hartigan-Go K, Thomas SH, Ford GA. Effect of oxybutynin on the QT interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 1996;41:73-5
   PubMed Web of Science ®Google Scholar
• Jones SE, Shuba LM, Zhabyeyev P, et al. Differencies in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K+ currents and action potentials. Br J Pharmacol 2000;131:245-54
   PubMed Web of Science ®Google Scholar
• Jones SE, Kasamaki Y, Shuba LM, et al. Analysis of the electrophysiologic effects of short-term oxybutynin on guinea pig and rabbit ventricular cells. J Cardiovasc Pharmacol 2000;35:334-40
   PubMed Web of Science ®Google Scholar
• Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of urinary incontinence. ICS guidelines 2009. 4th International Consultation on Incontinence. Curr Opin Urol 2009;19:380-94
   PubMed Web of Science ®Google Scholar
• Haruno A. Inhibitory effects of propiverine hydrochloride on the agonist-induced or spontaneous contractions of various isolated muscle preparations. Arzneimittelforschung 1992;42:815
   PubMed Web of Science ®Google Scholar
• Uchida S, Kurosawa S, Fujino Oki T, et al. Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain. Life Sci 2007;80:2454-60
   PubMed Web of Science ®Google Scholar
• Dorschner W, Stolzenburg JU, Griebenow R, et al. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. Eur Urol 2000;37:702-8
   PubMed Web of Science ®Google Scholar
• Dorschner W, Stolzenburg JU, Griebenow R, et al. The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine. Aktuelle Urol 2003;34:102-8
   PubMed Web of Science ®Google Scholar
• Wuest M, Christ T, Hiller N, et al. Effects of three metabolites of propiverine on voltage-dependent L-type calcium currents in human atrial myocytes. Eur J Pharmacol 2008;598:94-7
   PubMed Web of Science ®Google Scholar
• Christ T, Wettwer E, Wuest M, et al. Electrophysiological profile of propiverine – relationship to cardiac risk. Naunyn-Schmiedeberg's Arch Pharmacol 2008;376:431-40
   Google Scholar
• Donath F, Braeter M, Feustel C. The influence of propiverine hydrochloride on cardiac repolarization in healthy women and cardiac male patients. Int J Clin Pharmacol Ther 2011;49:353-65
   PubMed Web of Science ®Google Scholar
• Ohtake A, Ukai M, Hatanaka T, et al. In vitro ed in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004;492:243-50
   PubMed Web of Science ®Google Scholar
• Ikeda F, Kobayashi S, Suzuki M, et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedeberg's Arch Pharmacol 2002;366:97-103
   Google Scholar
• Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of Solifenacin succinate and extended release Tolderodine at treating overactive bladder syndrome: results of the STAR Trial. Eur Urol 2005;48:464-70
   PubMed Web of Science ®Google Scholar
• Choo MS, Lee JZ, Lee JB, et al. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomized, prospective, double-blind multicentre study. Int J Clin Pract 2008;62:1675-883
   PubMed Web of Science ®Google Scholar
• Oreskovic S, But I, Banovic M, Goldstjn MS. The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Coll Antropol 2012;36:243-8
   PubMed Web of Science ®Google Scholar
• Luo D, Liu L, Han P, et al. Solifenacin for overactive bladder: a systematic review and meta-analysis. Int Urogynecol J 2012;23:983-91
   PubMed Web of Science ®Google Scholar
• Smulders RA, Krauwinkel WJ, Swart PJ, Huang M. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol 2004;44:1023-33
   PubMed Web of Science ®Google Scholar
• Michel MC, Wetterauer U, Vogel M, de la Rosette JJ. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12 week, open-label, post-marketing surveillance study. Drug Saf 2008;31:505-14
   PubMed Web of Science ®Google Scholar
• Asajima H, Sekiguchi Y, Matsushima S, et al. QT prolongation and torsades des pointes associated with Solifenacin in an 81-year-old woman. Br J Clin Pharmacol 2008;66:896-7
   PubMed Web of Science ®Google Scholar
• Hoffstetter S, Che Leong F. Solifenacin succinate for the treatment of overactive bladder. Expert Opin Drug Metabol Toxicol 2009;5:345-50
   PubMed Web of Science ®Google Scholar
• Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 2001;41:298-304
   Google Scholar
• Rentzhog L, Stanton SL, Cardozo L, et al. Efficacy and safety of tolterodine in patients with detrusor instability: a dose- ranging study. Br J Urol 1998;81:42-8
   PubMedGoogle Scholar
• Nilvebrant L, Andersson KE, Gillberg PG, et al. Tolterodine a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997;327:195-207
   PubMed Web of Science ®Google Scholar
• Olshansky B, Foote J, Arguinzoniz M, et al. The effects of darifenacin and tolterodine on heart rate (HR) in patients with overactive bladder (OAB) [abstract 124]. Annual Meeting of the 92. International Continence Society; Christchurch, New Zealand. 2006. Available from: https://www.icsoffice.org/publications/2006/pdf/0124.pdf
   Google Scholar
• Schiffers M, Sauermann P, Schurch B, et al. The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects. World J Urol 2010;28:651-6
   PubMed Web of Science ®Google Scholar
• Pfizer Detrol® (tolterodine tartrate tablets) US prescribing information March, 2008. Available from: http://media.pfizer.com/files/products/uspi_detrol.pdf
   Google Scholar
• Hsiao SM, Chang TC, Wu WY, et al. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res 2011;37:1084-91
   PubMed Web of Science ®Google Scholar
• Kang J, Chen XL, Wang H, et al. Cardiac Ion Channel Effects of Tolterodine. JPET 2004;308:935-40
   PubMed Web of Science ®Google Scholar
• Malhotra BK, Glue P, Sweeney K, et al. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2007;81:377-85
   PubMed Web of Science ®Google Scholar
• Schwantes U, Topfmeier P. Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia-chances for improvement of therapy. Int J Clin Pharmacol Ther 1999;37:209-18
   PubMed Web of Science ®Google Scholar
• Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003;20:392-9
   PubMed Web of Science ®Google Scholar
• Pietzko A, Dimpfel W, Schwantes U, Topfmeier P. Influences of trospium chloride and oxybutynine on quantitative EEG in healthy volunteers. Eur Clin Pharmacol 1994;47:337-43
   Web of Science ®Google Scholar
• Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of trospium chloride on cytochrome P450 in human liver microsomes. Pharmacol Toxicol 1999;85:299-304
   PubMedGoogle Scholar
• Rovner ES. Trospium chloride in the management of overactive bladder. Drugs 2004;64:2433-46
   PubMed Web of Science ®Google Scholar
• Sanctura XR® (trospium chloride extended release). US prescribing information. Allergan, Inc; Irvine (CA): 2008
   Google Scholar
• Guay DR. Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Ther Cli Risk Manag 2005;1:157-67
   PubMedGoogle Scholar
• Dmochowski R, Staskin D. The Q-T interval and antimuscarinic drugs. Curr Urol Rep 2005;6:405-9
   PubMedGoogle Scholar
• Drici MD, Clément N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001;24:575-85
   PubMed Web of Science ®Google Scholar
• Colucci VJ, Rivey MP. Tolterodine-warfarin drug interaction. Ann Pharmacother 1999;33:1173-6
   PubMed Web of Science ®Google Scholar
• Taylor JR. Probable interaction between tolterodine and warfarin. Pharmacotherapy 2006;26:719-21
   PubMed Web of Science ®Google Scholar
• Glavind K, Chancellor M. Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity. Int Urogynecol J 2011;22:907-17
   PubMed Web of Science ®Google Scholar